RNA vaccine takes on malaria: early trial shows promise

NCT ID NCT06069544

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested an experimental RNA-based vaccine called BNT165e to see if it can prevent malaria. 163 healthy adults who had never had malaria received either the vaccine or a placebo. Researchers measured safety, immune responses, and whether the vaccine protected against a controlled malaria infection. The goal is to develop a new tool to fight malaria, a disease that affects millions worldwide.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
BNT165e (RNA-based malaria vaccine)
What this could lead to
If successful, this could lead to a new vaccine to prevent malaria, a major global health threat.
What could go wrong
This is an early-phase trial with only 163 participants, so results may not apply broadly. The vaccine may not provide strong or lasting protection, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALARIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • AMR Knoxville

    Knoxville, Tennessee, 37909, United States

  • AMR Las Vegas

    Las Vegas, Nevada, 89119, United States

  • AMR Tempe

    Tempe, Arizona, 85281, United States

  • Clinical Trials of Texas

    San Antonio, Texas, 78229, United States

  • University of Maryland, Center for Vaccine Development

    Baltimore, Maryland, 21201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.